Condition

Benign Prostatic Hyperplasia

ClinicalTrials.gov condition label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 34 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials34

Recruiting6

Common interventions25

Lead sponsors shown15

Clinical trials

34 shown

MRI-DTI Assessment of Urethral Internal Sphincter Ring and Prostate Base MorphologyNCT07694752 · 2026-07-15

Spinal Versus General Anesthesia in Open Simple ProstatectomyNCT07643415 · 2026-04-29

Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Prostate CancerNCT07526675 · 2026-04-10

Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer.NCT05148156 · 2026-02-11

Sacral Neuromodulation for Male Overactive Bladder (MOAB)NCT06511141 · 2024-10-22

Customized TULSA-PRO Ablation RegistryNCT05001477 · 2021-10-27

Urinary Function and Multimorbidity Risks: A Longitudinal Study in Beijing Community-Dwelling ElderlyNCT07357714 · 2026-01-01

NOT_YET_RECRUITING

Closed-System Bladder Irrigation to Reduce Urinary Tract Infections After Endoscopic Urologic Surgery (IRIS Trial)NCT07510685 · 2025-02-01

The Application of Multimodal Artificial Intelligence Systems in Prostate Cancer Diagnosis and Prognosis AnalysisNCT06589154 · 2024-10-10

PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTsNCT06051942 · 2022-11-22

ACTIVE_NOT_RECRUITING

Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery EmbolizationNCT04879940 · 2022-02-23

ACTIVE_NOT_RECRUITING

Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and PainNCT05803096 · 2021-12-12

Intravesical Prostatic Protrusion Mimicking Urothelial Cell Carcinoma of the BladderNCT05077852 · 2021-12-12

Evaluation of the Safety of the Treatment of Benign Prostatic Hyperplasia by High Intensity Focused Ultrasound.NCT04853914 · 2021-09-13

Anti-Androgen Treatment for COVID-19NCT04446429 · 2020-10-21

An Observational Study of Radial Access Embolization Procedures Using HydroPearl MicrospheresNCT04272216 · 2020-02-06

Learning Curve of Digital Rectal Examination for Prostate Cancer Among InternshipNCT03479359 · 2018-02-26

MRI Guided Transurethral HIFU for Various Prostate DiseasesNCT03350529 · 2017-07-24

Impact of Anticoagulants and Antiplatelets in Patients on Transurethral Resection of the ProstateNCT02822963 · 2016-03-01

Serum Copeptin as a Predictor of the Risk of Hyponatremia After Transurethral ProstatectomyNCT03912766 · 2016-02-01

Human Prostate Tissue Model to Maintain and Study Prostate Cancer Stem CellsNCT02425800 · 2015-07-28

Efficacy of Prostatic Artery Embolization (PAE) in Patients With Severe Benign Prostatic Hyperplasia (BPH)NCT02167919 · 2014-07-01

Application of DWI in Diagnosis of Prostate CancerNCT04962269 · 2013-06-12

2013 Annual National Digital Rectal Exam (DRE) Day StudyNCT01886547 · 2013-06-01

Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) LevelsNCT01678313 · 2012-08-01

Choline Metabolites in People With Prostate Cancer and Those With Benign HyperplasiaNCT06380062 · 2012-01-12

BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)NCT01520441 · 2011-03-01

3D Recording of a Trans-rectal Prostate BiopsyNCT01314456 · 2011-03-01

Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy OutcomeNCT01826617 · 2010-12-01

Korean Practice Patterns for Screening PCA(Prostate Cancer)NCT01371513 · 2010-05-01

Economic Analyses of the REDUCE TrialNCT01337258 · 2010-01-01

Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate CarcinomaNCT00400894 · 2005-09-01

Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate CancerNCT00375765 · 2005-04-01

Effects of Alpha Blockers on Prostate-specific Antigen (PSA) Change in Men With Lower Urinary Tract Symptoms (LUTS)NCT01250483 · 2001-01-01

Common interventions

Mapped drugs appearing in these trials

Shared trial participation only; not evidence of efficacy or approval.

dutasteride2 Botox1 placebo1

Leading sponsors

GlaxoSmithKline 3 St. Luke's Medical Center, Philippines 2 Ankara Training and Research Hospital 1 Applied Biology, Inc. 1 Axonics, Inc. 1 Benha University 1 Beth Israel Deaconess Medical Center 1 Buddhist Tzu Chi General Hospital 1 Changhai Hospital 1 Chinese PLA General Hospital 1 EDAP TMS S.A. 1 H. Lee Moffitt Cancer Center and Research Institute 1 HaEmek Medical Center, Israel 1 Hitit University 1 Jiangsu Taizhou People's Hospital 1

Trial status mix

COMPLETED19

RECRUITING6

UNKNOWN4

ACTIVE_NOT_RECRUITING2

WITHDRAWN2

NOT_YET_RECRUITING1

Phase mix

NA11

PHASE22

PHASE42

EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.